Pfizer Secures Key Approval for Weight-Loss Drug in China

Pfizer has achieved a significant milestone in the lucrative weight-loss medication sector, gaining regulatory approval for its drug in the highly competitive Chinese market. The National Medical Products Administration (NMPA) of China has cleared the GLP-1 agonist Ecnoglutide for long-term weight management in adults with obesity or overweight. This marks Pfizer’s first regulatory authorization for a GLP-1-based obesity treatment anywhere in the world.

A Strategic Move Preceded by a Major Deal

This approval follows a strategic licensing agreement finalized just months earlier. In February, Pfizer secured exclusive commercialization rights for Ecnoglutide in China through a partnership with Sciwind Biosciences. The total potential value of the deal, comprising an upfront payment and future milestone payments, could reach $495 million. According to the terms, Sciwind retains responsibility for the drug’s ongoing research, development, manufacturing, and supply.

Clinical Efficacy Backing the Decision

The regulatory green light is supported by robust clinical data demonstrating substantial weight reduction and metabolic benefits. In the pivotal Phase 3 “SLIMMER” trial, whose results were published in The Lancet Diabetes & Endocrinology, participants treated with Ecnoglutide experienced an average weight loss of 15.1% after 48 weeks. Study investigators noted no evidence of the effect plateauing. The treatment also showed positive impacts on secondary endpoints, including waist circumference, blood pressure, lipid profiles, and blood glucose levels, such as HbA1c.

Sciwind highlights the compound’s “cAMP-biased” mechanism of action, which is designed to offer a more precise approach for sustained weight reduction. Pfizer has not yet disclosed specific pricing details or an exact commercial launch date for the Chinese market.

Navigating a Crowded and Challenging Landscape

The authorization enters a rapidly expanding but already congested field. Rival GLP-1 therapies from Novo Nordisk, Eli Lilly, and Innovent Biologics are already available to patients in China. Compounding the competitive pressure, the patent for Novo Nordisk’s Wegovy is set to expire in China this very month, a development likely to intensify pricing pressure from more affordable biosimilar versions.

Should investors sell immediately? Or is it worth buying Pfizer?

For Pfizer, this transforms the approval into a commercial endurance test. Regulatory success alone is insufficient; the product must now prove its viability in a price-sensitive and fiercely contested environment.

Part of a Broader Strategic Pivot

Company leadership frames the Chinese approval as a single component within a much larger strategic push into obesity therapeutics. This initiative includes the recent $10 billion acquisition of Metsera and a licensing agreement with YaoPharma, potentially worth up to $2 billion. Pfizer has signaled that 2026 will be a pivotal development year, with plans to initiate more than 20 Phase 3 clinical studies across its obesity portfolio.

This aggressive expansion aligns with the company’s need to counter headwinds in its core business, where declining COVID-related revenue and patent expirations on other key drugs are constraining growth.

Market Performance and the Road Ahead

Investor sentiment remains measured. Pfizer shares closed at €23.30 on Friday, recording a year-to-date gain of 8.47%.

The strategic direction for the coming years is now clearly charted. Success will hinge on Pfizer’s ability to efficiently deliver on its promised clinical milestones and, more immediately, on whether Ecnoglutide can translate its regulatory victory into commercial success within the demanding Chinese marketplace.